牛牛AI助理已提取核心訊息
On March 7, 2024, Tonix Pharmaceuticals Holding Corp. announced the publication of a research paper in Psychiatry Research, detailing a Phase 3 trial of TNX-102 SL, a sublingual formulation of cyclobenzaprine, for the treatment of military-related posttraumatic stress disorder (PTSD). The study showed that TNX-102 SL is well-tolerated and demonstrated nominal improvement in PTSD severity and sleep quality within the first four weeks. These findings support the potential use of TNX-102 SL as a short-term treatment immediately following traumatic events. Additionally, the paper supports the upcoming Department of Defense-funded Phase 2 OASIS trial, which will evaluate the effects of TNX-102 SL on acute stress reaction and the prevention of PTSD after civilian motor vehicle collisions. The OASIS trial is expected to begin enrollment in the second quarter of 2024. Tonix also plans to submit a New Drug Application for TNX-102 SL, branded as Tonmya, for the management of fibromyalgia in the second half of 2024.
On March 7, 2024, Tonix Pharmaceuticals Holding Corp. announced the publication of a research paper in Psychiatry Research, detailing a Phase 3 trial of TNX-102 SL, a sublingual formulation of cyclobenzaprine, for the treatment of military-related posttraumatic stress disorder (PTSD). The study showed that TNX-102 SL is well-tolerated and demonstrated nominal improvement in PTSD severity and sleep quality within the first four weeks. These findings support the potential use of TNX-102 SL as a short-term treatment immediately following traumatic events. Additionally, the paper supports the upcoming Department of Defense-funded Phase 2 OASIS trial, which will evaluate the effects of TNX-102 SL on acute stress reaction and the prevention of PTSD after civilian motor vehicle collisions. The OASIS trial is expected to begin enrollment in the second quarter of 2024. Tonix also plans to submit a New Drug Application for TNX-102 SL, branded as Tonmya, for the management of fibromyalgia in the second half of 2024.
2024年3月7日，Tonix Pharmicals Holding Corp. 宣佈在《精神病學研究》上發表一篇研究論文，詳細介紹了用於治療軍事相關創傷後應激障礙（PTSD）的環苯扎林舌下製劑 TNX-102 SL 的三期試驗。該研究表明，TNX-102 SL 耐受性良好，在最初的四周內，創傷後應激障礙的嚴重程度和睡眠質量略有改善。這些發現支持創傷事件發生後立即使用 TNX-102 SL 作爲短期治療的可能性。此外，該論文支持即將進行的國防部資助的第二階段OASIS試驗，該試驗將評估 TNX-102 SL 對急性應激反應和民用機動車碰撞後創傷後應激障礙預防的影響。OASIS試驗預計將於2024年第二季度開始註冊。Tonix還計劃在2024年下半年提交一份名爲Tonmya的 TNX-102 SL新藥申請，用於治療纖維肌痛。
2024年3月7日，Tonix Pharmicals Holding Corp. 宣佈在《精神病學研究》上發表一篇研究論文，詳細介紹了用於治療軍事相關創傷後應激障礙（PTSD）的環苯扎林舌下製劑 TNX-102 SL 的三期試驗。該研究表明，TNX-102 SL 耐受性良好，在最初的四周內，創傷後應激障礙的嚴重程度和睡眠質量略有改善。這些發現支持創傷事件發生後立即使用 TNX-102 SL 作爲短期治療的可能性。此外，該論文支持即將進行的國防部資助的第二階段OASIS試驗，該試驗將評估 TNX-102 SL 對急性應激反應和民用機動車碰撞後創傷後應激障礙預防的影響。OASIS試驗預計將於2024年第二季度開始註冊。Tonix還計劃在2024年下半年提交一份名爲Tonmya的 TNX-102 SL新藥申請，用於治療纖維肌痛。
有用
沒用